Investor Presentation regarding Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

ANUPAM RASAYAN INDIA LTD. ARILSLDSTX20260814043 Date: August 14, 2026 To, T o , BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, ‘Exchange Plaza’, C-1, Block-G, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai-400001, India Mumbai-400051, India SCRIP CODE: 543275 SYMBOL: ANURAS Dear Sir/Madam, Subject: Investor Presentation- Q1 of FY27 Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the ‘Investor Presentation’ in respect of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, of Anupam Rasayan India Limited (the “Company”). The Investor Presentation will also be hosted on the website of the Company at www.anupamrasayan.com. We request you to kindly note the same and take into your records. Thanking you, Yours Faithfully, For Anupam Rasayan India Limited Ashish Gupta Company Secretary & Compliance Officer Encl.: As above Registered Office: Tel. : +91-261-2398991-95 Office Nos. 1101 to 1107, 11th Floor, Icon Rio, Fax : +91-261-2398996 Behind Icon Business Centre, Dumas Road, E-mail : office@anupamrasayan.com Surat-395007, Gujarat, India. Website : www.anupamrasayan.com CIN - L24231GJ2003PLC042988 Anupam Rasayan India Limited Q1 FY27 Investor Presentation Safe Harbour AAnnuuppaamm RRaassaayyaann IInnddiiaa LLiimmiitteedd || ‹2#› This presentation and the accompanying slides (the “Presentation”), which have been prepared by Anupam Rasayan India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe to any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over-runs on contracts, our ability to manage our international operations, government policies and actions, regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company. Quarterly Highlights Quarterly Financial Highlights AAnnuuppaamm RRaassaayyaann IInnddiiaa LLiimmiitteedd || ‹4#› Consolidated Consolidated Consolidated Added Total Revenue EBITDA* Profit After Tax 3 New ₹6,675 Mn ₹1,749 Mn ₹512 Mn Products in Q1FY27 Y-o-Y growth of 36% Y-o-Y growth of 35% Y-o-Y growth of 6% taking total to 125+ Standalone Standalone Standalone Total Revenue EBITDA* Profit After Tax Products ₹3,349 Mn ₹1,155 Mn ₹320 Mn Y-o-Y growth of 4% Y-o-Y growth of 17% Y-o-Y growth of 8% *Includingotherrevenue Key Highlights AAnnuuppaamm RRaassaayyaann IInnddiiaa LLiimmiitteedd || ‹5#› Financials New Products Commercialized • Consolidated Total Income for the quarter came in at Rs 6,675 Mn with a • Pharma Segment: Added 1 new intermediate for new drug to the portfolio, strong growth of 36% on a YoY basis driven by new product commercialization further strengthening our offerings and expanding opportunities in the and healthy demand across all segments pharmaceutical segment.. • Consolidated EBITDA for the quarter also grew by 35% on YoY basis and came • Performance Material Segment: Added 2 new products used as monomer for in at Rs 1,749 Mn with margins at 26% showcasing our continuous focus on high new reinforced polyester and high-performance engineering fluid, broadening value products. our product portfolio and strengthening our capabilities to cater to evolving customer requirements. New Development Acquisition • World's first company to commercialize ETFA (Ethyl Trifluoroacetate) using • Bliss GVS Pharma acquisition progressing as planned, expected to strengthen flow chemistry. Anupam's pharmaceutical platform through regulated manufacturing and enhanced CDMO capabilities. • Signed an LoI with BASQUEVOLT, S.A., creating a potential revenue opportunity of up to $300 million over a 10-year period with expected • Successfully completed the acquisition of Jayhawk Fine Chemicals, commercialization in FY27 strengthening its globally integrated specialty chemicals and CDMO platform with enhanced manufacturing footprint, advanced chemistry capabilities, high- • Well-positioned for the next growth phase, driven by increasing contribution value chemistries, and strong proforma annual performance. from Performance Materials and Pharmaceuticals, strong customer engagement, and expanding global opportunities. Managing Director’s Message AAnnuuppaamm RRaassaayyaann IInnddiiaa LLiimmiitteedd || ‹6#› Mr. Anand S Desai MANAGING DIRECTOR "We are pleased to begin fiscal year 2027 on a strong note. Consolidated Revenue for the quarter grew 36% year-on-year, a result that reflects sustained momentum across our businesses and continued execution of our strategy to build a globally integrated specialty chemicals and CDMO platform. We would like to highlight an important technological milestone achieved during the quarter. We became the first company in the world to commercialize Ethyl Trifluoroacetate, or ETFA, using flow chemistry — a significant advancement that further strengthens our capabilities in complex fluorination. We also signed a Letter of Intent with BASQUEVOLT, S.A. for the potential long-term supply of a specialty chemical product. This represents a revenue opportunity of approximately US$300 million spread over a period of ten years. Turning to our pharmaceutical business, the proposed acquisition of Bliss GVS Pharma continues to progress as planned, following the signing of the definitive agreement. Upon completion, we expect this transaction to strengthen our pharmaceutical platform through synergies across CDMO capabilities, product development, customer relationships, and access to regulated markets. Looking ahead, we remain confident in our growth prospects. This confidence is supported by a strong product pipeline, expanding opportunities across our Performance Materials and Pharmaceuticals segments, deeper customer engagement, and continued investment in technology and innovation. Together, these initiatives position us well to deliver sustainable growth and long-term value creation." Consolidated Quarterly Profit & Loss Statement AAnnuuppaamm RRaassaayyaann IInnddiiaa LLiimmiitteedd || ‹7#› Mr. Anand S Desai Particulars (₹ Mn) Q1FY27 Q1FY26 YoY FY26 MANAGING DIRECTOR Revenue from Operations 6,550 4,858 23,655 Other [Showing first 8,000 characters — download PDF for full document]